WATERTOWN, Mass., Feb 24, 2022 (GLOBE NEWSWIRE via COMTEX) --
WATERTOWN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc.
, a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 3, 2022 to report its fourth quarter and full-year 2021 financial results and highlight recent corporate developments.
To access the live conference call, please dial (877) 312-7507 (domestic) or (631) 813-4828 (international) and reference conference ID 5058194. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com . A webcast replay will also be available on the corporate website at the conclusion of the call.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals /zigman2/quotes/210537129/composite EYPT -3.02% is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert [(R)] technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert's proven intravitreal drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ [(R)] for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Green Room Communications
Is there a problem with this press release? Contact the source provider Comtex at firstname.lastname@example.org. You can also contact MarketWatch Customer Service via our Customer Center.
(C) Copyright 2022 GlobeNewswire, Inc. All rights reserved.